Evidence map›Paper›PMID 34543267›Full record

Trial reportPLoS medicine2021

Effect of a patient-centered hypertension delivery strategy on all-cause mortality: Secondary analysis of SEARCH, a community-randomized trial in rural Kenya and Uganda.

Matthew D Hickey, James Ayieko, Asiphas Owaraganise, Nicholas Sim, Laura B Balzer, Jane Kabami, Mucunguzi Atukunda, Fredrick J Opel, Erick Wafula, Marilyn Nyabuti and 12 more

Registry-linked trialOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in PLoS medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01864603 (Sustainable East Africa Research in Community Health), which is not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01864603 nacompletednot on this map

Sustainable East Africa Research in Community Health

TypeinterventionalSponsorUniversity of California, San FranciscoRan2013 to 2021Enrolled150,395ConditionsHIV, Tuberculosis, Hypertension, DiabetesArmsUniversal ART in a streamlined care model, Annual Community Health Campaigns, Targeted PrEP and Targeted testing interventions, Baseline community-based HIV and multi-disease testing
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Community-Wide Universal HIV Test and Treat Intervention Reduces Tuberculosis Transmission in Rural Uganda: A Cluster-Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 3 countries.

Matthew D HickeyDivision of HIV, ID, & Global Medicine, Department of Medicine, UCSF, San Francisco, California, United States of America.ORCID 0000-0001-8913-1602
James AyiekoCentre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
Asiphas OwaraganiseInfectious Disease Research Collaboration, Kampala, Uganda.ORCID 0000-0002-5594-0310
Nicholas SimSchool of Public Health, University of California Berkeley, Berkeley, California, United States of America.ORCID 0000-0001-8321-3076
Laura B BalzerSchool of Public Health & Health Sciences, University of Massachusetts Amherst, Amherst, Massachusetts, United States of America.ORCID 0000-0002-3730-410X
Jane KabamiInfectious Disease Research Collaboration, Kampala, Uganda.
Mucunguzi AtukundaInfectious Disease Research Collaboration, Kampala, Uganda.ORCID 0000-0003-4762-0728
Fredrick J OpelCentre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
Erick WafulaCentre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
Marilyn NyabutiCentre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.ORCID 0000-0002-9860-136X
Lillian BrownDivision of HIV, ID, & Global Medicine, Department of Medicine, UCSF, San Francisco, California, United States of America.ORCID 0000-0003-1809-3762
Gabriel ChamieDivision of HIV, ID, & Global Medicine, Department of Medicine, UCSF, San Francisco, California, United States of America.ORCID 0000-0002-5860-8081
Vivek JainDivision of HIV, ID, & Global Medicine, Department of Medicine, UCSF, San Francisco, California, United States of America.
James PengDivision of HIV, ID, & Global Medicine, Department of Medicine, UCSF, San Francisco, California, United States of America.
Dalsone KwarisiimaUnited States Agency for International Development, Kampala, Uganda.
Carol S CamlinCenter for AIDS Prevention Studies & Department of Medicine, UCSF, San Francisco, California, United States of America.ORCID 0000-0001-5615-1164
Edwin D CharleboisCenter for AIDS Prevention Studies & Department of Medicine, UCSF, San Francisco, California, United States of America.ORCID 0000-0001-7237-2119
Craig R CohenDepartment of Obstetrics, Gynecology & Reproductive Sciences, UCSF, San Francisco, California, United States of America.ORCID 0000-0001-8654-6634
Elizabeth A BukusiCentre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.ORCID 0000-0002-2031-2808
Moses R KamyaInfectious Disease Research Collaboration, Kampala, Uganda.
Maya L PetersenSchool of Public Health, University of California Berkeley, Berkeley, California, United States of America.
Diane V HavlirDivision of HIV, ID, & Global Medicine, Department of Medicine, UCSF, San Francisco, California, United States of America.
Kenya Medical Research Institute · KEInfectious Diseases Research Collaboration · UGSan Francisco AIDS Foundation · USUniversity of California, Berkeley · USUnited States Agency for International Development · USUniversity of Massachusetts Amherst · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
Reducing Failure-to-Initiate ART: Streamlined ART Start Strategy (START)U01AI099959 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2012 to 2016
$39.7M
Targeted Learning using adaptive designs for HIV Epidemic control in East AfricaR01AI074345 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI PETERSEN, MAYA LIV, VANDERLAAN, MARK J · 2007 to 2023
$6.6M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
NIAID NIH HHS R01 AI074345NIAID NIH HHS T32 AI060530NIAID NIH HHS U01 AI099959NIAID NIH HHS UM1 AI068636NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

backgroundHypertension treatment reduces morbidity and mortality yet has not been broadly implemented in many low-resource settings, including sub-Saharan Africa (SSA). We hypothesized that a patient-centered integrated chronic disease model that included hypertension treatment and leveraged the HIV care system would reduce mortality among adults with uncontrolled hypertension in rural Kenya and Uganda. METHODS AND

findingsThis is a secondary analysis of the SEARCH trial (NCT:01864603), in which 32 communities underwent baseline population-based multidisease testing, including hypertension screening, and were randomized to standard country-guided treatment or to a patient-centered integrated chronic care model including treatment for hypertension, diabetes, and HIV. Patient-centered care included on-site introduction to clinic staff at screening, nursing triage to expedite visits, reduced visit frequency, flexible clinic hours, and a welcoming clinic environment. The analytic population included nonpregnant adults (≥18 years) with baseline uncontrolled hypertension (blood pressure ≥140/90 mm Hg). The primary outcome was 3-year all-cause mortality with comprehensive population-level assessment. Secondary outcomes included hypertension control assessed at a population level at year 3 (defined per country guidelines as at least 1 blood pressure measure <140/90 mm Hg on 3 repeated measures). Between-arm comparisons used cluster-level targeted maximum likelihood estimation. Among 86,078 adults screened at study baseline (June 2013 to July 2014), 10,928 (13%) had uncontrolled hypertension. Median age was 53 years (25th to 75th percentile 40 to 66); 6,058 (55%) were female; 677 (6%) were HIV infected; and 477 (4%) had diabetes mellitus. Overall, 174 participants (3.2%) in the intervention group and 225 participants (4.1%) in the control group died during 3 years of follow-up (adjusted relative risk (aRR) 0.79, 95% confidence interval (CI) 0.64 to 0.97, p = 0.028). Among those with baseline grade 3 hypertension (≥180/110 mm Hg), 22 (4.9%) in the intervention group and 42 (7.9%) in the control group died during 3 years of follow-up (aRR 0.62, 95% CI 0.39 to 0.97, p = 0.038). Estimated population-level hypertension control at year 3 was 53% in intervention and 44% in control communities (aRR 1.22, 95% CI 1.12 to 1.33, p < 0.001). Study limitations include inability to identify specific causes of death and control conditions that exceeded current standard hypertension care.

conclusionsIn this cluster randomized comparison where both arms received population-level hypertension screening, implementation of a patient-centered hypertension care model was associated with a 21% reduction in all-cause mortality and a 22% improvement in hypertension control compared to standard care among adults with baseline uncontrolled hypertension. Patient-centered chronic care programs for HIV can be leveraged to reduce the overall burden of cardiovascular mortality in SSA.

trial registrationClinicalTrials.gov NCT01864603.

Indexed as

Community Health ServicesDelivery of Health Care, IntegratedPatient-Centered CareAdolescentAdultAgedAnti-HIV AgentsAntihypertensive AgentsBlood PressureCause of DeathDiabetes MellitusFemaleHIV InfectionsHumansHypertensionHypoglycemic AgentsAnti-HIV AgentsAntihypertensive AgentsHypoglycemic Agents

Identifiers

PMID34543267
PMCPMC8489716
OpenAlexW3200496730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.